Hyperoxaluria Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, by DelveInsight | Alnylam Pharma, Genentech, Dicerna Pharma, Pfizer Inc., Zhejiang Tianxin Pharma, Wuxi Further

June 24 09:05 2024
Hyperoxaluria Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, by DelveInsight | Alnylam Pharma, Genentech, Dicerna Pharma, Pfizer Inc., Zhejiang Tianxin Pharma, Wuxi Further
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hyperoxaluria pipeline constitutes 8+ key companies continuously working towards developing 8+ Hyperoxaluria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Hyperoxaluria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Hyperoxaluria Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hyperoxaluria Market.


Some of the key takeaways from the Hyperoxaluria Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Hyperoxaluria treatment therapies with a considerable amount of success over the years. 

  • Hyperoxaluria companies working in the treatment market are Alnylam Pharmaceuticals, Biocodex, Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others, are developing therapies for the Hyperoxaluria treatment 

  • Emerging Hyperoxaluria therapies in the different phases of clinical trials are- Lumasiran, nedosiran, Stiripentol Oral Capsule, DCR-PHXC, CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others are expected to have a significant impact on the Hyperoxaluria market in the coming years.

  • In October 2023, Novo Nordisk has gained approval from the US Food and Drug Administration (FDA) for Rivfloza (nedosiran) injection. This treatment aims to lower urinary oxalate levels in children aged nine and older, as well as adults with primary hyperoxaluria type 1 (PH1) who have relatively preserved kidney function. PH1 is a rare genetic disorder causing the liver to overproduce oxalate, affecting about one in 38,600 people globally. The approval covers Rivfloza dosages of 80mg, 128mg, or 160mg, administered monthly via subcutaneous ribonucleic acid interference therapy. This decision was based on data from the pivotal Phase II PHYOX2 clinical trial and interim results from the ongoing Phase III PHYOX3 extension study.

  • In July 2023, BioMarin has completed the multi-ascending dose study of BMN 255 for hyperoxaluria in chronic liver disease in healthy volunteers. Early data showed a rapid and significant increase in plasma glycolate following BMN 255 treatment. BioMarin plans to begin enrolling patients with chronic liver disease and hyperoxaluria in an expanded study in the second half of 2023. The company believes that BMN 255, a potent, orally bioavailable small molecule, could significantly reduce the disease and treatment burden for this patient population with significant unmet needs.


Hyperoxaluria Overview

Hyperoxaluria is a medical condition characterized by an excessive amount of oxalate in the urine. Oxalate is a natural chemical in the body, and it is also found in certain foods. In hyperoxaluria, high levels of oxalate can lead to the formation of kidney stones and other complications.


Get a Free Sample PDF Report to know more about Hyperoxaluria Pipeline Therapeutic Assessment



Emerging Hyperoxaluria Drugs Under Different Phases of Clinical Development Include:

  • Lumasiran: Alnylam Pharmaceuticals

  • Stiripentol Oral Capsule: Biocodex

  • DCR-PHXC: Dicerna Pharmaceuticals

  • CHK-336: Chinook Therapeutics

  • BBP-711: Cantero Therapeutics

  • BMN 255: BioMarin Pharmaceutical, Inc

  • Oxabact: OxThera

  • Nedosiran: Dicerna Pharmaceuticals, Inc.


Hyperoxaluria Route of Administration

Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

  • Molecule Type


Hyperoxaluria Molecule Type

Hyperoxaluria Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type


Hyperoxaluria Pipeline Therapeutics Assessment

  • Hyperoxaluria Assessment by Product Type

  • Hyperoxaluria By Stage and Product Type

  • Hyperoxaluria Assessment by Route of Administration

  • Hyperoxaluria By Stage and Route of Administration

  • Hyperoxaluria Assessment by Molecule Type

  • Hyperoxaluria by Stage and Molecule Type


DelveInsight’s Hyperoxaluria Report covers around 8+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration


Further Hyperoxaluria product details are provided in the report. Download the Hyperoxaluria pipeline report to learn more about the emerging Hyperoxaluria therapies


Some of the key companies in the Hyperoxaluria Therapeutics Market include:

Key companies developing therapies for Hyperoxaluria are – Alnylam Pharmaceuticals, Inc., Genentech, Inc., Dicerna Pharmaceuticals, Inc., Pfizer Inc., Zhejiang Tianxin Pharmaceutical Co., Wuxi Further Pharmaceutical Co Ltd, Tecoland Corporation, Takeda Pharmaceuticals Company Limited, Intellia Therapeutics, Inc., and others.


Hyperoxaluria Pipeline Analysis:

The Hyperoxaluria pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Hyperoxaluria with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hyperoxaluria Treatment.

  • Hyperoxaluria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Hyperoxaluria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hyperoxaluria market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Hyperoxaluria drugs and therapies


Hyperoxaluria Pipeline Market Drivers

  • Rising Prevalence of Hyperoxaluria, increasing demand of disease specific novel treatment are some of the important factors that are fueling the Hyperoxaluria Market.


Hyperoxaluria Pipeline Market Barriers

  • However, high cost of treatment and diagnosis for Hyperoxaluria, limited research and development for treatment and other factors are creating obstacles in the Hyperoxaluria Market growth.


Scope of Hyperoxaluria Pipeline Drug Insight    

  • Coverage: Global

  • Key Hyperoxaluria Companies: Alnylam Pharmaceuticals, Biocodex, Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others

  • Key Hyperoxaluria Therapies: Lumasiran, nedosiran, Stiripentol Oral Capsule, DCR-PHXC, CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others

  • Hyperoxaluria Therapeutic Assessment: Hyperoxaluria current marketed and Hyperoxaluria emerging therapies

  • Hyperoxaluria Market Dynamics: Hyperoxaluria market drivers and Hyperoxaluria market barriers 


Request for Sample PDF Report for Hyperoxaluria Pipeline Assessment and clinical trials


Table of Contents

1. Hyperoxaluria Report Introduction

2. Hyperoxaluria Executive Summary

3. Hyperoxaluria Overview

4. Hyperoxaluria- Analytical Perspective In-depth Commercial Assessment

5. Hyperoxaluria Pipeline Therapeutics

6. Hyperoxaluria Late Stage Products (Phase II/III)

7. Hyperoxaluria Mid Stage Products (Phase II)

8. Hyperoxaluria Early Stage Products (Phase I)

9. Hyperoxaluria Preclinical Stage Products

10. Hyperoxaluria Therapeutics Assessment

11. Hyperoxaluria Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hyperoxaluria Key Companies

14. Hyperoxaluria Key Products

15. Hyperoxaluria Unmet Needs

16 . Hyperoxaluria Market Drivers and Barriers

17. Hyperoxaluria Future Perspectives and Conclusion

18. Hyperoxaluria Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/